• 1
    Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994; 266: 6671.
  • 2
    Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995; 378: 789792.
  • 3
    Pierce L. Radiotherapy for breast cancer in BRCA1/BRCA2 carriers: clinical issues and management dilemmas. Semin Radiat Oncol. 2002; 12: 352361.
  • 4
    Foulkes WD, Wong N, Brunet JS, et al. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res. 1997; 3: 24652469.
  • 5
    Gaffney DK, Brohet RM, Lewis CM, et al. Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol. 1998; 47: 129136.
  • 6
    Verhoog LC, Brekelmans CT, Seynaeve C, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet. 1998; 351: 316321.
  • 7
    Robson M, Levin D, Federici M, et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst. 1999; 91: 21122117.
  • 8
    Pierce LJ, Strawderman M, Narod SA, et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol. 2000; 18: 33603369.
  • 9
    Pierce L, Levin A, Rebbeck T, et al. Ten-year outcome of breast-conserving surgery (BCS) and radiotherapy (RT) in women with breast cancer (BC) and germline BRCA 1/2 mutations: results from an international collaboration [abstract]. Breast Cancer Res Treat. 2003; 82: S7.
  • 10
    Delaloge S, Kloos I, Ariane D, et al. Young age is the major predictor of local relapse among conservatively treated BRCA1-, BRCA2-, or non-BRCA-linked hereditary breast cancer (BC) [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 11.
  • 11
    Robson ME, Chappuis PO, Satagopan J, et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res. 2004; 6: R8—R17.
  • 12
    Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004; 22: 23282335.
  • 13
    Turner BC, Harrold E, Matloff E, et al. BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. J Clin Oncol. 1999; 17: 30173024.
  • 14
    Haffty BG, Harrold E, Khan AJ, et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet. 2002; 359: 14711477.
  • 15
    Bremer M, Doerk T, Sohn C, Karstens JH. Local relapse after post-operative radiotherapy in patients with bilateral breast cancer by BRCA1/2 status [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 11.
  • 16
    Seynaeve C, Verhoog LC, van de Bosch LM, et al. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer. 2004; 40: 11501158.
  • 17
    Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002; 20: 36283636.
  • 18
    Chabner E, Nixon A, Gelman R, et al. Family history and treatment outcome in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer. J Clin Oncol. 1998; 16: 20452051.
  • 19
    Freedman LM, Buchholz TA, Thames HD, et al. Local-regional control in breast cancer patients with a possible genetic predisposition. Int J Radiat Oncol Biol Phys. 2000; 48: 951957.
  • 20
    Haas JA, Schultz DJ, Peterson ME, Solin LJ. An analysis of age and family history on outcome after breast-conservation treatment: the University of Pennsylvania experience. Cancer J Sci Am. 1998; 4: 308315.
  • 21
    Harrold EV, Turner BC, Matloff ET, et al. Local recurrence in the conservatively treated breast cancer patient: a correlation with age and family history. Cancer J Sci Am. 1998; 4: 302307.
  • 22
    Simmonds P, Eccles D, Goddard J, Evans G, Lalloo F, Royle G. Is breast conservation appropriate for women with hereditary breast cancer [abstract]? Proc Am Soc Clin Oncol. 1999; 18: 612a.
  • 23
    Vlastos G, Mirza NQ, Meric F, et al. Breast-conservation therapy in early-stage breast cancer patients with a positive family history. Ann Surg Oncol. 2002; 9: 912919.
  • 24
    Verhoog LC, Brekelmans CT, Seynaeve C, Meijers-Heijboer EJ, Klijn JG. Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer. 2000; 83: 384386.
  • 25
    Foulkes WD, Wong N, Brunet JS, Narod SA. BRCA mutations and survival in breast cancer. J Clin Oncol. 1998; 16: 32063208.
  • 26
    Foulkes WD, Wong N, Rozen F, Brunet JS, Narod SA. Survival of patients with breast cancer and BRCA1 mutations. Lancet. 1998; 351: 13591360.
  • 27
    Robson M, Gilewski T, Haas B, et al. BRCA-associated breast cancer in young women. J Clin Oncol. 1998; 16: 16421649.